Welcome to our dedicated page for Climb Bio SEC filings (Ticker: CLYM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Climb Bio, Inc. (Nasdaq: CLYM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Climb Bio is a clinical-stage biotechnology company developing monoclonal antibody therapeutics for immune-mediated and B-cell mediated diseases, and its filings offer structured insight into how it reports material events, governance changes, and financial updates.
Recent Form 8-K filings describe key developments such as quarterly financial results, publication of clinical data for budoprutug in primary membranous nephropathy, and new preclinical data for CLYM116 in IgA nephropathy. Other 8-Ks detail the appointment of senior executives, including the Chief Financial Officer, and related equity awards granted under the company’s 2025 Inducement Plan, as well as amendments to increase the share reserve under that plan. These documents also confirm that Climb Bio’s common stock trades on The Nasdaq Global Market under the symbol CLYM.
Through Stock Titan, users can review Climb Bio’s SEC filings alongside AI-powered summaries that highlight the main points of each document. This includes explanations of how the company characterizes the therapeutic potential and clinical development of budoprutug and CLYM116 in its disclosures, and how it describes risks and forward-looking statements associated with its programs. The filings page is also a resource for tracking regulatory communications around investor events, data releases, and other reportable events.
By using this page, investors and researchers can quickly locate Climb Bio’s 8-Ks and other SEC reports and rely on AI-generated overviews to understand the significance of each filing without reading every line of the underlying documents.
Climb Bio, Inc. reported that investment entities affiliated with RA Capital acquired pre-funded warrants linked to its common stock. The filing shows an indirect grant of 2,106,000 Pre-Funded Warrants, each exercisable for one share of common stock.
The warrants were acquired at $9.4999 per warrant and have a nominal exercise price of $0.0001 per share. They are exercisable immediately and have no expiration date, but their exercise is limited so that RA Capital–affiliated holders and related groups cannot beneficially own more than 33.0% of Climb Bio’s outstanding common stock after exercise. Following this grant, the reporting RA Capital entities show 22,546,000 pre-funded warrants beneficially owned, subject to footnoted pecuniary-interest and beneficial-ownership disclaimers.
RA Capital Management and affiliates report a significant position in Climb Bio, Inc., beneficially owning 22,631,401 shares of common stock, or 33.0% of the class. The stake includes common shares, stock options and pre-funded warrants that are exercisable within 60 days, subject to ownership limits.
The filing details an April 2026 private placement in which Climb Bio issued 9,481,000 common shares at $9.50 per share and 2,106,000 pre-funded warrants at $9.4999 each. RA Capital’s fund purchased all 2,106,000 pre-funded warrants for $20,006,789.40, funded from its working capital.
The pre-funded warrants are exercisable at $0.0001 per share and do not expire, but a 33.0% beneficial ownership blocker restricts further exercise above that threshold. Climb Bio agreed to register for resale both the private placement shares and the warrant shares under a registration rights agreement that includes filing deadlines, effectiveness requirements and potential liquidated damages.
Climb Bio, Inc. entered into a securities purchase agreement for a private placement of its common equity. The company is selling 9,481,000 common shares at $9.50 per share and pre-funded warrants to purchase 2,106,000 shares at $9.4999 per warrant, for aggregate gross proceeds of about $110.0 million before fees.
Each pre-funded warrant is immediately exercisable at $0.0001 per share, subject to beneficial ownership limits generally at 4.99% or 9.99%, and up to 33.0% for RA Capital, with an overall cap of 19.99% for other holders. Climb Bio also agreed to register the resale of the new shares and warrant shares within 45 days after closing, and states that existing cash plus anticipated net proceeds are expected to support continued execution toward late-stage development of its immune-mediated disease pipeline.
Climb Bio, Inc. will hold its 2026 annual stockholder meeting virtually on June 5, 2026 at 9:00 a.m. Eastern via www.proxydocs.com/CLYM, with a record date of April 7, 2026.
Stockholders will vote on electing two Class II directors, ratifying PricewaterhouseCoopers LLP as auditor for 2026, amending the certificate of incorporation to change how directors may be removed for cause, and amending the 2021 Equity Incentive Plan so its automatic share pool increase includes prefunded warrants. The company describes its classified board, committee structure, independence determinations, insider-trading and clawback policies, and executive compensation. In 2025, the CEO earned a $669,500 salary and $2.92 million in total compensation, and the auditor billed $686,400 in fees. A quorum requires a majority of outstanding common shares, noted as approximately 47,768,543 shares.
Climb Bio, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders, to be held virtually on June 5, 2026. Stockholders will vote on the election of two Class II directors, ratification of PricewaterhouseCoopers LLP as auditor, an amendment to the charter regarding removal for “cause,” and an amendment to the 2021 Equity Incentive Plan to include prefunded warrants in the automatic annual share-pool increase. The record date for voting is April 7, 2026, with approximately 47,768,543 shares outstanding as of that date. The proxy statement is marked preliminary — subject to completion and materials (including the 2025 Annual Report and Form 10-K) are available online.
Climb Bio, Inc. reported that Senior Vice President, Finance and principal accounting officer Cindy Driscoll will separate from the company by mutual agreement, effective April 30, 2026. This creates a leadership change in the finance organization.
Chief Financial Officer Dr. Susan Altschuller, who has served as CFO since October 2025, will also become the company’s principal accounting officer as of the separation date. The company highlights her extensive prior CFO and financial leadership roles in several biopharmaceutical companies and notes that her existing compensation arrangements remain unchanged. The filing also states that she has no disclosable related-party transactions or family relationships with directors or officers.
Climb Bio, Inc. is a clinical-stage biotechnology company focused on immune-mediated diseases. Its lead antibody, budoprutug, targets CD19 to deplete pathogenic B cells in primary membranous nephropathy (pMN), immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE). Budoprutug has orphan-drug designation for pMN, encouraging Phase 1b data in pMN, and multiple ongoing Phase 1/2 trials in pMN, ITP and SLE, including an intravenous and a high‑concentration subcutaneous formulation.
The company’s second program, CLYM116, is a next-generation anti‑APRIL ‘sweeper’ antibody aimed at IgA nephropathy and other B‑cell–mediated diseases. Early preclinical work suggests deep and durable APRIL and IgA suppression, and Phase 1 trials in healthy volunteers and parallel studies with partner Mabworks in China are underway. Climb Bio estimates its targeted indications encompass more than 500,000 U.S. patients, with broader potential across roughly 2 million people living with immune‑mediated diseases.
Climb Bio, Inc. reported fourth quarter and full-year 2025 results showing continued investment in its immune-mediated disease pipeline and a stronger balance sheet. Cash, cash equivalents and marketable securities were $160.7 million as of December 31, 2025, which the company expects will fund operations into 2028.
Full-year 2025 research and development expenses rose to $46.7 million from $14.3 million, while general and administrative expenses increased to $21.2 million from $16.0 million, reflecting pipeline and corporate growth. Net loss narrowed to $59.9 million in 2025 from $73.9 million in 2024, with loss per share improving to $0.88 from $1.53.
The company highlighted progress in multiple clinical programs. Budoprutug is in ongoing trials for primary membranous nephropathy, immune thrombocytopenia and systemic lupus erythematosus, plus a completed Phase 1 study of a subcutaneous formulation, with initial data from several studies expected in 2026. CLYM116 is in a Phase 1 healthy volunteer study, supported by a partner-led Phase 1/2 trial in IgA nephropathy.
Climb Bio, Inc. director Thomas Stephen Basil reported selling a total of 50,000 shares of Common Stock in open-market transactions under a pre-arranged Rule 10b5-1 trading plan. On February 25, 2026, he sold 33,687 shares at a weighted average price of $7.0046 per share, followed by 16,313 shares on February 26, 2026 at a weighted average price of $7.0060 per share. The filing notes that each day’s sales occurred in multiple trades within price ranges from $7.0000 to $7.0600 and from $7.0000 to $7.0400, respectively. After these transactions, Basil directly owned 154,657 shares.